News

Targeted Oncology2h
Luspatercept Outperforms ESA in Duration of Anemia Response in MDS
During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndromes.
The Lancet1d
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase ... - The Lancet
Myelodysplastic syndromes are haematopoietic stem cell neoplasms with characteristic dysplasia in the blood and bone marrow cells resulting in ineffective haematopoiesis, cytopenias, and increased ...
Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells
ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...
The American Journal of Managed Care6d
Venetoclax Duration Does Not Significantly Impact OS in AML or MDS
Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded ...